Showing 1 posts of 1 posts found.
Pharma companies were able to negotiate far fewer so-called ‘pay to delay’ cases as a strategy to stave off generic …
Long-acting therapies set to reshape HIV treatment market
MHRA authorises Lynkuet for hot flushes linked to breast cancer therapy
MHRA approves Romvimza for tenosynovial giant cell tumour
NICE recommends allergy immunotherapy tablets for younger children
Dunbar Pharmaceuticals and IPS Pharma announce distribution agreement